Youthfill Filler 1.1ml — Korean HA Filler in Fine, Deep & Shape with HoPE™ Technology

Youthfill Filler is a Korean cross-linked hyaluronic acid dermal filler manufactured by RF Bio Co. Ltd. in South Korea. All three variants — Fine, Deep, and Shape — share a 24 mg/mL HA base with 0.3% premixed lidocaine, supplied as 1.1 mL pre-filled syringes. The product is built on RF Bio’s patented HoPE™ (Homogeneous Process and Equilibration) cross-linking technology and carries triple regulatory certification: KFDA, US FDA, and EU EDQM.

HoPE™ stands for Homogeneous Process and Equilibration — RF Bio’s proprietary cross-linking process. It produces a uniformly cross-linked HA gel with consistent particle distribution throughout the matrix, contrasting with conventional cross-linking that can leave heterogeneous high- and low-density zones. The result is more predictable injection handling, smoother extrusion, high storage modulus (G’ — gel firmness), and low enzymatic degradation rate.

All three share the same 24 mg/mL HA base and 0.3% premixed lidocaine — variant differentiation comes entirely from cross-linking density. Youthfill Fine (low density) treats superficial wrinkles in the upper dermis: crow’s feet, fine perioral lines, under-eye hollows, and lip body hydration. Youthfill Deep (medium density) addresses nasolabial folds, marionette lines, and moderate facial sculpting in the deep dermis. Youthfill Shape (high density) is the SUB-Q variant for deep subcutaneous placement: cheekbone augmentation, chin and jawline contouring, non-surgical rhinoplasty.

Yes — Youthfill carries US FDA approval in addition to Korean KFDA registration and European EDQM (European Medicines Quality Commission) certification. This triple regulatory profile is shared by very few Korean dermal fillers. Verify the current FDA 510(k) clearance status at the FDA Premarket Notification database before importation, as approval scope and expiry dates may change.

Per RF Bio clinical data, Youthfill delivers 6–12 months of correction depending on variant and treatment area. Youthfill Fine in superficial dermis typically lasts shorter (6 months in lips, longer in lower-movement zones). Youthfill Shape in subcutaneous tissue often delivers the full 12 months due to lower metabolic turnover in deep layers. Individual duration depends on dose, patient metabolism, and facial movement intensity.

Youthfill’s documented endotoxin level is less than 0.04 IU/mg — significantly below the international safety threshold for injectable medical devices (typically 0.5 IU/mg). Low endotoxin reduces the risk of post-injection inflammation, granuloma formation, and delayed hypersensitivity reactions. RF Bio achieves this through stringent raw material screening and the HoPE™ purification process. The result: documented allergy risk under 0.1%, eliminating the need for pre-procedure skin testing in most patient profiles.

Youthfill is manufactured by RF Bio Co. Ltd., a South Korean medical device manufacturer founded in 2019. RF Bio specialises in dermal fillers and cosmetic medical devices, with HoPE™ technology as their flagship intellectual property. The company holds KFDA, FDA, and EDQM certifications across the Youthfill product line.

Yes — full-face protocols combining all three variants are standard practice. A typical session might use Youthfill Shape for jawline and chin contour, Youthfill Deep for nasolabial folds and cheek volume, and Youthfill Fine for perioral fine lines or under-eye refinement. Because all three variants share the same 24 mg/mL HA base and HoPE™ technology, layered biocompatibility is consistent across the protocol.

Store between 2 °C and 25 °C, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

Per RF Bio’s documented allergy risk of less than 0.1%, pre-procedure skin testing is generally not required for most patients. However, practitioners should still conduct a comprehensive patient screening including: history of severe allergies, prior reactions to HA fillers, hypersensitivity to gram-positive bacterial proteins (used in HA fermentation), and current medications. Patients with documented allergy history or autoimmune conditions may warrant individual case-by-case assessment.